Mentions
Extended reach
Total likes
Video views
AI synopsis
This collection of discussions reflects a consensus that the study's long-term data reveal comparable mortality rates for monitoring, surgery, or radiotherapy, with phrases like 'low prostate-cancer specific mortality regardless of treatment' and 'outcomes much the same.' The tone varies from analytical to optimistic, emphasizing the study's importance for informed decision-making and highlighting the relevance of findings such as minimal differences in 15-year survival and treatment side effects.
Most discussions recognize that the 15-year outcomes show similar survival rates across different treatments, indicating general agreement on the study's findings.
Comments demonstrate a moderate level of interest, with references to long-term follow-up and implications for treatment choices.
Many discuss details like mortality percentages, treatment comparisons, and implications, showing active engagement.
Diverse discussions highlight how these results could influence clinical decisions and patient management, indicating a high impact.
「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと思っています。 https://t.co/pqUP6MQKeZ
ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment (published in @NEJMEvidence) https://t.co/kfN14ICogM
The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by prostate-specific antigen (PSA) testing. Read the full ProtecT trial Research Summary: https://t.co/G2ABkMk0TI
AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Journal of Medicine, 2023). Study findings analyzed and evaluated by artificial intelligence.
Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/qsxX9zmH0O
Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupos (vigilância ativa X radioterapia X prostatectomia) e acompanhou por 15 anos. - Resultado: mortalidade similar nos três grupos. https://t.co/HN9dRxoSLi https://t.co/sx3XQZ4eOm
Prostate biopsies may cause more harm than good, including complications and cancer spread. Many prostate cancers are nonaggressive, so understanding safer, evidence-based monitoring options is essential for informed…
Managing an Elevated PSA and avoiding unnecessary prostate biopsies. Dr. Stephen Petteruti discusses when a measured approach is best, highlighting alternatives like advanced imaging and lifestyle changes to support…
This episode examines the risks behind traditional PSA tests and prostate biopsies, challenging conventional protocols. Dr. Stephen Petteruti explores alternative approaches to prostate health, emphasizing proactive…
The Intellectual Medicine Approach offers a proactive strategy to fight prostate cancer, emphasizing vitality preservation and alternative therapies. This method aims to help men address the disease head-on while…
RT @OsinskiReflex: @AnilMakam @AppleHelix So I will bite on this one. You are wrong. The 15 year follow-up from pivot showed treatment of…
@AnilMakam @AppleHelix So I will bite on this one. You are wrong. The 15 year follow-up from pivot showed treatment of localized diseased decreased the development of metastatic disease by about 50% (about 10% to about 5%). I still don’t know how you figure you who is who? https://t.co/WIEFCXrwiQ
@AshwinShindeMD Protect trial: AS =annual visit with 6 mo PSA after yr1. Trigger was doubling of PSA in 12 months - or "concern". If that is stressing the system, it speaks to the system collective resources. And if they can't treat the IR or HR cancers, they find... https://t.co/f5Y90J3rPS
15 year Protect trial did show an increase in metastasis in patients choosing active monitoring (in a majority low-risk cohort). https://t.co/YCS8iWqLFK
@sasha_latypova Likely a good bet. Cheers
#EAU23 Los tratamientos radicales condujeron a la mitad de la incidencia de metástasis y progresión local como monitoreo activo sin afectar a la supervivencia específica de la enfermedad o general (ensayo ProtecT) https://t.co/b7HqhOnuK3
https://t.co/Zjvbjit43F https://t.co/w9A8EcUbDr Please share with the urologist community as I’m unable to make sense of these results. #prostatecancer
RT @NL_Magazin:
NEJM: 5 year survival (prostate metastases): ▪️
RT @NL_Magazin:
RT @NL_Magazin:
@rewcastle_john In fact, 99/1643 (6%) patients had GG3+, and 275 had GG2. Of GG3, ~30 each had RP, RT, and surveillance. Study did not have power to detect survival differences in such a small subgroup. /1 https://t.co/oVN0ZEt2em
@RWMaloneMD Link to the study which show there is no substantial statistical difference in therapy outcomes as compared to "active monitoring". Cheers
No Uro On Time desta semana, Dr. Luís César Zaccaro fala sobre os resultados obtidos pelo estudo “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer”, publicado em 2023 no The New England Journal of Medicin. Assista! #sbusp #cancerdeprostata https://t.co/qHXaBA58Eq
@BrendonStilesMD The Protect Trial has already delivered the long term outcome data (15 years!). NEJM https://t.co/TABGQkDrhF It’s all over for prostatectomy now. The bowel bother for men is very minimal with SBRT. Not in same league as wearing pads and high impotence rates with surgery
@rlfeng @nataliagandur @EUplatinum @OncoAlert Unfortunately studies like these are limited by unmeasured confounders https://t.co/vFsvVaa4iY and not supported by randomised evidence https://t.co/7RtCoisYCn hence the need for men to make well informed decisions through multidisciplinary consultation https://t.co/eAhTXif3Op
RT @ZeMoyra: @faznet Lang erwartet Ja, aber 1 Jahr publiziert https://t.co/PtuUMFtTaW
RT @ZeMoyra: @faznet Lang erwartet Ja, aber 1 Jahr publiziert https://t.co/PtuUMFtTaW
King Charles III Diagnosed With Cancer This article should cheer everyone up. It’s on prostate cancer mortality risk. https://t.co/5VtyTH7AdZ https://t.co/B2bkajbwn2
@faznet Lang erwartet Ja, aber 1 Jahr publiziert https://t.co/PtuUMFtTaW
RT @uroegg: In my utopian world, every prostate cancer doc and patient with early stage PrCa understands details of this landmark trial, co…
@5_utr @ProtonStorey @seanmmcbride Huh?!? Not aware of any data in ProtecT to support that statement. Please share and educate me/us https://t.co/Wh694XI4pr
RT @rewcastle_john: @DrChoueiri @Nicp85Pavan @OncoAlert @TargetedOnc @OncLive @gotoPER @FDAOncology @OncBrothers @ASCO @myESMO @AACR @Ameri…
@DrChoueiri @Nicp85Pavan @OncoAlert @TargetedOnc @OncLive @gotoPER @FDAOncology @OncBrothers @ASCO @myESMO @AACR @AmericanCancer @DanaFarber @DanaFarber_GU @DanaFarberNews @NEJM @JCO_ASCO https://t.co/11jpwqHnSH I would have like to have seen ProtecT on this list. It has shaken the knowledge foundation of localized prostate cancer treatment.
@yawnyame @RSNA @DanLinMD @spsutkaMD @PGrivasMDPhD @ChapinMD @RichMatulewicz @dr_coops Big policy paper https://t.co/EMzPPTz7Bt. Of interest to radiology https://t.co/3e6mRYGUSf Two RCTs https://t.co/VWQVv7mBaq & https://t.co/ZFOINk6oIb About screening https://t.co/NemmAI0xcg & https://t.co/9IZLNUfW4d
RT @tyabu7973: 前立腺癌の治療RCT ProtectT試験の15年長期予後を見た前向きコホート。 1600人強を①経過観察、②前立腺摘出、③放射線治療に分けて、15年後の前立腺癌死亡に有意差なし。そもそも前立腺癌死亡率は2.7%。 英国の50-69歳のPSA検診陽…
早期の前立腺がんでは手術と放射線と採血のどれを選んでも死亡率に差がなかったと。 それじゃ、ほとんど人は採血を選ぶでしょう。１０年ぐらい経ったら、医師は前立腺がん手術のことをなんて酷い治療をしていたのかと反省する日が来るかもしれない。 #がん https://t.co/aPU28GeUCg
@SaiKate108 @TaniaLe84494434 Published Mar 11 2023 with results of 15 year randomized controlled study on specific mortality of localized prostate cancer. Regardless of treatment option survival rate is 96-98%. Cheers C in C 1st St Nicolaas Army Army Group True North⚔️☠️
@SPuro88 Radiotherapy is as effective an option as surgery for prostate and muscle invasive bladder cancer https://t.co/ZqvzkHyk22 https://t.co/7RtCoisYCn @TargetingCancer #radonc #pcsm #blcsm
RT @EAU_Uroonco:
RT @EAU_Uroonco:
@JGomezRivas @uroegg @dr_coops @EfstathiouEleni @docjavip @dralvaropinto @DrSopenaSutil @dra_cienfuegos @dr_rajwa @joniau @PucheSanz @GUOaeu @veerukasi @declangmurphy @mrsprostate @evacomperat @EAU_YAUProstate @dperfen @enriquegomezgo4 @GGandaglia @GGiannarini @Tilki_De @philcornford @ChapinMD - MRI in screening https://t.co/ZckIu3Y7OY - ProtecT https://t.co/UTSgheS1b1 - TP biopsy https://t.co/WlXNfX1tDU
@deverynross After 15 years of follow-up, prostate cancer–specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer https://t.co/AtKoHC8DeM
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
RT @EvidenceOpen: AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Jour…
AI Review of "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" (The New England Journal of Medicine, 2023). Study findings analyzed and evaluated by artificial intelligence.
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM - https://t.co/Uvgq15sULT https://t.co/vV6CJo66Ii
#UroSoMe #urology #ProstateCancer when #NEJM accept a paper is a must to read https://t.co/ycL9aTZTxy
RT @ESTRO_RT: #ESTROnewsletter Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/QkZ0V0rn2D…
#ESTROnewsletter Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/QkZ0V0rn2D https://t.co/LbvW5sZaaY
Fuente: https://t.co/rEhVqiGSvm
15 year data from the #ProtecT-Trial
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/4pT5z0IBNS
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
Net uit. Onderzoekers volgden 15 jaar lang mannen na een diagnose van lokale prostaatkanker. Een groep kreeg geen behandeling, een groep chirurgie, een groep bestraling. Wat blijkt? De overlevingskansen in de groep zonder behandeling waren even groot. https://t.co/auRj09GS1e
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
そのまま日本人にあてはめられませんが、重要なデータです。国内のいろいろなデータベースの解析が待たれます。 https://t.co/DG8SkOHwg0
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
RT @NEJM: This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT st…
This week’s most shared article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT study) https://t.co/G2ABkMkyJg https://t.co/ab6SnuJr2E
RT @drol007: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/9epp0jL4Vn
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/9epp0jL4Vn
RT @RevistaMFSamfyc: Resultados a los quince años tras monitorización, cirugía o radioterapia en el cáncer de próstata https://t.co/XAEBhj9…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer Between 1999 and 2009 in the United Kingdom, 82,429 men between 50 and 69 years of age received a prostate-specific antigen (PSA) test. Localized prostate cancer was diagnosed in 2664 men. Of https://t.co/z8V9zKVOK3
RT @BTFCancerNews: ProtecT Trial: At a median follow-up of 15 years, mortality from PSA-detected prostate cancer remained low regardless of…
ProtecT Trial: At a median follow-up of 15 years, mortality from PSA-detected prostate cancer remained low regardless of the type of treatment: active monitoring, prostatectomy, or radiotherapy. https://t.co/0Pw4lUZloM #PCSM
Resultados a los quince años tras monitorización, cirugía o radioterapia en el cáncer de próstata https://t.co/XAEBhj9pl0 PMID 36912538
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM - https://t.co/J4ZICphTZN https://t.co/uYG9UCNWML #prostate
Fifteen-Year Outcomes after #Monitoring, #Surgery, or #Radiotherapy for #ProstateCancer A nice study documenting the nearly identical outcomes of either definitive surgery or radiation therapy for prostate cancer.
RT @tyabu7973: 前立腺癌の治療RCT ProtectT試験の15年長期予後を見た前向きコホート。 1600人強を①経過観察、②前立腺摘出、③放射線治療に分けて、15年後の前立腺癌死亡に有意差なし。そもそも前立腺癌死亡率は2.7%。 英国の50-69歳のPSA検診陽…
RT @tyabu7973: 前立腺癌の治療RCT ProtectT試験の15年長期予後を見た前向きコホート。 1600人強を①経過観察、②前立腺摘出、③放射線治療に分けて、15年後の前立腺癌死亡に有意差なし。そもそも前立腺癌死亡率は2.7%。 英国の50-69歳のPSA検診陽…
RT @tyabu7973: 前立腺癌の治療RCT ProtectT試験の15年長期予後を見た前向きコホート。 1600人強を①経過観察、②前立腺摘出、③放射線治療に分けて、15年後の前立腺癌死亡に有意差なし。そもそも前立腺癌死亡率は2.7%。 英国の50-69歳のPSA検診陽…
前立腺癌の治療RCT ProtectT試験の15年長期予後を見た前向きコホート。 1600人強を①経過観察、②前立腺摘出、③放射線治療に分けて、15年後の前立腺癌死亡に有意差なし。そもそも前立腺癌死亡率は2.7%。 英国の50-69歳のPSA検診陽性患者対象でした。 ...経過観察で良いなあ https://t.co/GprAPsYsgv
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
Resultados a los 15 años después del control, la cirugía o la radioterapia para el cáncer de próstata localizado: La mortalidad específica por cáncer de próstata fue baja independientemente del tratamiento asignado... https://t.co/FTpytUQwrz
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/r4dNBAqP4M
“After 15 years of follow-up, prostate cancer–specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer.” https://t.co/5h2IktjFDf
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/kQ5uohU1yu…
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/kQ5uohU1yu…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @vitorborin_: Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupo…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @BijoyTelivala: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM #prostate #cancer 15 yr f…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
RT @stephenjduckett: Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate C…
Spoiler alert: outcomes much the same. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/qsxX9zmH0O
Prostate cancer–specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer #nejm #cancer #research https://t.co/PsjBwHYsuX
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM #prostate #cancer 15 yr f / U Death around 2.5 % in all 3 arms inc observation https://t.co/VwiiftMRSV
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/p7uTa7GmRw ECA https://t.co/IA4P1ykCK1 Editorial https://t.co/QIqAfQPKU2 Comentario https://t.co/1tDNDEUYYL Vídeo resumen https://t.co/gRoJPLICM3…
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/kQ5uohU1yu…
RT @vitorborin_: Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupo…
RT @vitorborin_: Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupo…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/2cGFgIcPFJ
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer - https://t.co/J4ZICphTZN https://t.co/3Jdjv1m8qx #prostate
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/kQ5uohU1yu…
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
RT @vitorborin_: Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupo…
Publicado o trial ProtecT: - ECR que dividiu pacientes com câncer de próstata localizado diagnosticado por PSA em 3 grupos (vigilância ativa X radioterapia X prostatectomia) e acompanhou por 15 anos. - Resultado: mortalidade similar nos três grupos. https://t.co/HN9dRxoSLi https://t.co/sx3XQZ4eOm
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/Y80o9kcXi4
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
Some great examples: ProtecT https://t.co/LDurDncX7f @NEJM https://t.co/ZnSYadCABi
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
RT @NEJM: The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by…
The relative effectiveness of treatment strategies for localized prostate cancer remains uncertain, even with early detection by prostate-specific antigen (PSA) testing. Read the full ProtecT trial Research Summary: https://t.co/G2ABkMk0TI
RT @airhop_poitiers: Résultats à 15 ans de patients atteints d’un cancer de prostate localisé diagnostique sur une élévation du PSA pris en…
RT @LGSentinel: "After 15 years of follow-up prostate cancer–specific mortality was low regardless of treatment assigned. Thus, choice of t…
"After 15 years of follow-up prostate cancer–specific mortality was low regardless of treatment assigned. Thus, choice of therapy involves weighing trade-offs between benefits & harms associated with treatments for localized prostate cancer." https://t.co/KvuSv8C48S
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/CdvsjUzxDk
RT @rincondesisifo: (NEJM) Resultados, tras 15 años de seguimiento, de 3 estrategias de abordaje del ca de próstata https://t.co/kQ5uohU1yu…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM - https://t.co/0oB9517EN5 https://t.co/LDjc1Rxd4g
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/sCIzJC4dX4
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer shows no real mortality benefit with slight lean towards tx in those under <65 | @NEJM @NEJMres360 https://t.co/ytepusNaux
En pacientes con cáncer de próstata no hay diferencias en la mortalidad entre tratar con prostatectomía, radioterapia o seguimiento monitorizado. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/cGPXTE5Jld
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM - https://t.co/J4ZICphTZN https://t.co/i6aKQa79Xi #prostate
RT @MLPOncoData: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/EvrxXYLzNW https://t.co/…
RT @MLPOncoData: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/EvrxXYLzNW https://t.co/…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/kUjdwSZh3F
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/EvrxXYLzNW https://t.co/0SWc8Anwet
RT @elliotthaut: As I get older, I pay more attention to papers about prostate cancer. “Fifteen-Year Outcomes after Monitoring, Surgery,…
As I get older, I pay more attention to papers about prostate cancer. “Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer” @NEJM https://t.co/QU5khj5dod
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
Prostate cancer treatment can wait for most men, study finds https://t.co/O2z6GSpaEl https://t.co/NNZap3qEVT https://t.co/bF8hMqK4Db
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/MMkIfhuvht
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
RT @NEJM: ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Pat…
ProtecT study: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/G2ABkMk0TI Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment (published in @NEJMEvidence) https://t.co/kfN14ICogM
RT @XBayona:
RT @CalaisJeremie: 15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patien…
RT @CalaisJeremie: 15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patien…
2/n ... Here are the 2 @NEJM studies "Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer" https://t.co/zIqbzddkYU via @Freddie_Hamdy et al https://t.co/AOJPbhu7z6
RT @CalaisJeremie: 15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patien…
RT @CalaisJeremie: 15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patien…
RT @CalaisJeremie: 15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patien…
15-year Outcomes of the Triple-arm randomized trial of active monitoring vs prostatectomy vs radiotherapy In 1600 patients with localized prostate cancer. Prostate cancer–specific mortality was low regardless of the treatment assigned. Toxicity matters. https://t.co/JJXS7Kc4im
Reference (https://t.co/n44CrOvQbe)
4) https://t.co/ZEAtWxCdiq
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM - https://t.co/Uvgq15sULT https://t.co/AZrtbOejr8
RT @Mat_Guc: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer: ProtecT Study
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/MMkIfhtXrV
低リスクだったら監視→再生検→放射線てのが一番バランス取れている感じ？ Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/njhI7s1FFt
RT @NEJM: Original Article: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer (ProtecT trial) https://t.…
@LTCTheresaLong Oh my dear you are so right. As to prostate cancer, I came across a very interesting 15 year longitudinal study. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer Helped me make the correct decision. Cheers!☠️
RT @GlobalPHObserv: Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/drQezS4Quk
英国で8万人を超える男性の15年調査研究発表(ニューイングランドジャーナルオブメディスン) “結論 15 年間の追跡調査の後、割り当てられた治療に関係なく、前立腺がん特異的死亡率は低かった” 治療してもしなくても死因が癌だとは言えない https://t.co/NaTv1wpbs7 https://t.co/4jHwSJapPv
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer | NEJM https://t.co/IM1BcTWc37 Some good news!
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer https://t.co/YiehqO8ipY
RT @rtakenakatky: 「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと…
" After 15 years of follow-up, prostate cancer–specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized #prostatecancer ." https://t.co/nUBOCJCdZv
RT @rtakenakatky: 「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと…
RT @rtakenakatky: 「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと…
RT @rtakenakatky: 「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと…
「泌尿器科志望です」という学生や研修医に、泌尿器科はなんといっても前立腺がんとの戦いになるから、放射線治療も同等の成績だし医者のQOLも良いよ！と熱烈に勧誘して入局に至った事が複数回あるので、放射線治療の勧誘は泌尿器科人気に便乗するのが良いと思っています。 https://t.co/pqUP6MQKeZ
New research helps to confirm that active surveillance or monitoring men with prostate cancer versus treating it early (i.e. surgery, radiation, etc.) is also a reasonable option for most men. Generally most prostate cancers grow slowly and as a result https://t.co/Zx8JtJ3GIq
15-year follow up from localized prostate cancer after positive PSA test: ⚰️prostate cancer 2.7% (45 men) - 3.1% active-monitoring - 2.2% prostatectomy - 2.9% radiotherapy p=0.53 ⚰️ any cause 21.7% (356 men). https://t.co/9cIUyzEZ1P
15-year follow up from localized prostate cancer after positive PSA teset: ⚰️prostate cancer 2.7% (45 men) - 3.1% active-monitoring - 2.2% prostatectomy - 2.9% radiotherapy p=0.53 ⚰️ any cause 21.7% (356 men). https://t.co/D8MABNwAyK
1-82 bin erkeğe prostat spesifik antijen (PSA) testi uygulandı. Lokalize prostat kanseri 2664 erkekte teşhis edildi. Bu erkeklerden 1643'ünün; 545'i aktif izleme, 553'ü prostatektomi (ameliyat) ve 545'i radyoterapi aldı. https://t.co/fzMiBKrKYy
JL
TM